Gilead Sciences has been a relatively solid performer this year in the biotech sector as its peers have struggled. The stock is up nearly 15% year-to-date, lagging the S&P 500. Yet it's rebounded 35% ...
Generating income has consistently been a primary goal for investors. To achieve this, they often opt for investments that provide steady and reliable returns over time.
Jaylyn Pruitt is currently an associate editor for Health.com, where she covers sleep products. Lauren Paige Richeson is a writer and editor at Health. She's the author of Avocado Obsession ...